Who Paid My Doc
Paul Matherne
Family Medicine Gulfport, MS Medical Doctor
NPI 1730245739 CMS profile 214784
1924 E Pass Rd, Suite 225, Gulfport, MS 39507
General payments
$9,376
Research payments
$1,131
Ownership & investment interest
$0
Research they led as principal investigator
$14,426,661
Through program year 2025, Paul Matherne of Gulfport, MS is reported in the CMS Open Payments database as having received $9,376 across 124 general payments and $1,131 in research payments paid to them. Separately, studies naming them as principal investigator received $14,426,661 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $606 | 2 | |
| 2024 | General | $1,822 | 10 | |
| 2023 | General | $1,319 | 11 | |
| 2022 | Research | $936 | 3 | |
| 2021 | General | $350 | 22 | |
| 2021 | Research | $195 | 1 | |
| 2020 | General | $383 | 25 | |
| 2019 | General | $4,895 | 54 |
Beside peers
- Paul Matherne
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Paul Matherne were reported at $606. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Paul Matherne | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,895 | $150 | $41–$543 | $163 |
| 2020 | $383 | $120 | $32–$415 | $114 |
| 2021 | $350 | $137 | $35–$551 | $132 |
| 2022 | $0 | $137 | $37–$512 | $149 |
| 2023 | $1,319 | $149 | $42–$545 | $160 |
| 2024 | $1,822 | $156 | $44–$560 | $164 |
| 2025 | $606 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 165 drugsPart D claims
10,198
Drug cost
$639,240
Branded share of claims
20.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 106 | $131,618 | |
| Januvia Sitagliptin Phosphate | Brand | 68 | $59,733 | |
| Trulicity Dulaglutide | Brand | 31 | $52,986 | |
| Jardiance Empagliflozin | Brand | 38 | $41,481 | |
| Myrbetriq Mirabegron | Brand | 54 | $37,246 | |
| Eliquis Apixaban | Brand | 63 | $34,442 | |
| Xarelto Rivaroxaban | Brand | 36 | $28,423 | |
| Farxiga Dapagliflozin Propanediol | Brand | 35 | $26,038 | |
| Invokana Canagliflozin | Brand | 22 | $22,350 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 11 | $15,273 |
The 10 drugs with the highest cost, of 165 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 28 billing codesPaid by Medicare
$60,330
Medicare patients
338
Services billed
1,152
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Diabetes | 25% | |
| Ischemic heart disease | 25% | |
| COPD | 17% | |
| Cancer | 13% | |
| Osteoporosis | 13% | |
| Atrial fibrillation | 12% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 | Office | 15 | 16 | $350 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 39 | 40 | $179 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
128 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Mississippi
Related records
Family Medicine in Mississippi
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Mississippi
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.